Loading
LB4330 is an experimental fusion protein from L & L Bio, Ningbo, China in phase 2 trials, aimed at Claudin 18.2.
LB4330 is a fusion protein developed by L & L Bio, Ningbo, China. Its target is Claudin 18.2 (the sponsor names Claudin18.2 x IL-10). The sponsor states: Anti-Claudin18.2/IL-10 fusion protein combining tumour-antigen targeting with an immunomodulatory cytokine, given in combination with LB1410. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06468358, plans to enrol 194 participants with primary completion expected 2026-12-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Anti-Claudin18.2/IL-10 fusion protein combining tumour-antigen targeting with an immunomodulatory cytokine, given in combination with LB1410. Connects to Claudin 18.2.
1.LB4330 binds Claudin 18.2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"LB4330" OR ABSTRACT:"LB4330") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LB4330, not a curated reading list.
Shares A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors, Hutchmed and the tag pipeline.
Shares Hutchmed and the tag pipeline.
Shares Hutchmed and the tag pipeline.
Shares Hutchmed and the tag pipeline.
Shares Hutchmed and the tag pipeline.
Shares Hutchmed and the tag pipeline.
Shares Hutchmed and the tag pipeline.
Shares Claudin 18.2 and the tag pipeline.